An observational study in Acute Coronary Syndrome, Gender and Genetic Predisposition, sponsored by IRCCS San Raffaele. Recruiting at 4 sites in Italy. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Acute Coronary Syndrome with a site in Italy — 25 open to participants now, 30 under way, 2 of them phase 3. Acute Coronary Syndrome · Italy.
Among the 138 studies in Acute Coronary Syndrome with a site in Italy, this one is the 45th largest by planned enrollment of the 52 observational ones that give a count, is one of 7 that started in 2025, is one of 53 observational ones, reaches primary completion later than 9 of the 29 other live ones, and was the 121st registered.
1,489 studies on the registry are indexed under Acute Coronary Syndrome; 271 are open to participants now.
Browse Acute Coronary Syndrome studies →25 of the 138 studies in Acute Coronary Syndrome with a site in Italy are open now. Recruiting first, the newest first:
Casa di Cura Dott. Pederzoli · Sites in Italy
Ages 30–70
Fondazione Ricerca e Innovazione Cardiovascolare ETS · Sites in Italy
Abcentra · Sites in Italy, United States, Czechia and 6 more countries
Ages 18+
Heart Care Foundation · Sites in Italy
Ages 18+
IRCCS San Raffaele · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 100 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.
Median enrollment 522 across the 85 interventional studies, 1,000 across the 52 observational. Of the 75 that completed or were terminated, 20 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 138 have an industry lead sponsor. The 10 most frequent:
IRCCS San Raffaele is the lead sponsor of 454 studies on the registry; 235 are open to participants now.
IRCCS San Raffaele has 3 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
9 of the studies in Acute Coronary Syndrome with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07440381Phase 3Heart Care FoundationtriPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE | 2027-08 |
| NCT07588295Maria Cecilia HospitalLocal And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease | 2026-12 |
| NCT01218776University of BolognaInternational Survey of Acute Coronary Syndromes | 2026-12-31 |
| NCT06927739AbcentraFocused Orticumab Research for Treating Inflammation in Coronary Arteries | 2027-02-08 |
| NCT07429227Casa di Cura Dott. PederzoliEvaluation Through Innovative Examinations of Intestinal Dysbiosis Status in Patients Diagnosed With Cardiovascular Diseases and Evaluation of the Efficacy of Natural and Probiotic Extracts in the Non-pharmacological Approach to Improving Intestinal Dysbiosis Status. | 2027-03 |
Add all 9 to your calendar (.ics) → With an account.
Among the 138 studies in Acute Coronary Syndrome with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Create a multicenter prospective registry that collects information from women affected by acute coronary syndrome (ACS). This registry aims to understand the diversity in the presentation of women with ACS. It proposes to conduct a thorough characterization of the women involved in the study through genetic, biochemical, and molecular analysis.This approach aims to identify any differences in the characteristics of women with ACS and to identify disease subtypes that may influence treatment options and clinical outcomes.
Create a multicenter prospective registry that collects information from women affected by acute coronary syndrome (ACS) from a wide range of cultural and ethnic backgrounds distributed across various Italian regions. This registry aims to understand the diversity in the presentation of women with ACS in Italy, providing valuable data for a better understanding of the disease.
Additionally, it proposes to conduct a thorough characterization of the women involved in the study through genetic, biochemical, and molecular analysis. This analysis will be stratified by age and the etiology of coronary artery disease, distinguishing between obstructive and non-obstructive coronary artery disease.
Specific aims of this proposal are:
The study will include female patients presenting with ACS (according to ESC guidelines)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Female patient presenting with ACS (age \>/= 18)
Multicentric Registry
The aim will be to create a prospective multicenter registry of gender, diversity and inclusion (GEDI) of women with Acute Coronary Syndrome
Time frame: 12 months of follow-up
Plan to share: Undecided
Ran from Jan 2025 to primary completion in Feb 2026, 13 months.
Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's 13 months is below that.
Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.